Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition.
Luye QinKaijie MaZi-Jun WangZihua HuEmmanuel MatasJing WeiZhen YanPublished in: Nature neuroscience (2018)
Haploinsufficiency of the SHANK3 gene is causally linked to autism spectrum disorder (ASD), and ASD-associated genes are also enriched for chromatin remodelers. Here we found that brief treatment with romidepsin, a highly potent class I histone deacetylase (HDAC) inhibitor, alleviated social deficits in Shank3-deficient mice, which persisted for ~3 weeks. HDAC2 transcription was upregulated in these mice, and knockdown of HDAC2 in prefrontal cortex also rescued their social deficits. Nuclear localization of β-catenin, a Shank3-binding protein that regulates cell adhesion and transcription, was increased in Shank3-deficient mice, which induced HDAC2 upregulation and social deficits. At the downstream molecular level, romidepsin treatment elevated the expression and histone acetylation of Grin2a and actin-regulatory genes and restored NMDA-receptor function and actin filaments in Shank3-deficient mice. Taken together, these findings highlight an epigenetic mechanism underlying social deficits linked to Shank3 deficiency, which may suggest potential therapeutic strategies for ASD patients bearing SHANK3 mutations.
Keyphrases
- histone deacetylase
- autism spectrum disorder
- traumatic brain injury
- mental health
- healthcare
- genome wide
- intellectual disability
- attention deficit hyperactivity disorder
- binding protein
- transcription factor
- dna methylation
- end stage renal disease
- cell adhesion
- gene expression
- ejection fraction
- chronic kidney disease
- newly diagnosed
- genome wide identification
- cell proliferation
- adipose tissue
- type diabetes
- signaling pathway
- copy number
- dna damage
- metabolic syndrome
- single molecule
- replacement therapy
- risk assessment
- insulin resistance
- peritoneal dialysis
- cell migration
- human health
- skeletal muscle
- preterm birth